top of page

ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly

2 hours ago
1 min read

She describes how the first trials will target glioma, a type of brain cancer, and Siren has also done work to show that the approach could be a universal therapy that may have utility against numerous cancers. Plus, how Siren did a unique crowdfunded $5 million fundraise.

https://vimeo.com/1192026810

Coverage brought to you by

Recent Posts

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

ASGCT 2026: Encoded Therapeutics presented updated clinical data today for its gene therapy program targeting Dravet Syndrome with 52 weeks of follow up

ASGCT 2026: Encoded Therapeutics presented updated clinical data today for its gene therapy program targeting Dravet Syndrome with 52 weeks of follow up

ASGCT 2026: Dispatch Bio is trying to solve the solid tumor challenge for CAR-T by designing bespoke antigens that light up tumors. At ASGCT, they also have data on a unique cytokine for armoring CARs

ASGCT 2026: Dispatch Bio is trying to solve the solid tumor challenge for CAR-T by designing bespoke antigens that light up tumors. At ASGCT, they also have data on a unique cytokine for armoring CARs

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page